Literature DB >> 14747659

Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten.

Stéphanie A Backman1, Danny Ghazarian, Kelvin So, Otto Sanchez, Kay-Uwe Wagner, Lothar Hennighausen, Akira Suzuki, Ming-Sound Tsao, William B Chapman, Vuk Stambolic, Tak W Mak.   

Abstract

PTEN is a tumor suppressor gene mutated in various advanced human neoplasias, including glioblastomas and prostate, breast, endometrial, and kidney cancers. This tumor suppressor is a lipid phosphatase that negatively regulates cell survival and proliferation mediated by phosphatidylinositol 3-kinase/protein kinase B signaling. Using the Cre-loxP system, we selectively inactivated Pten in murine tissues in which the MMTV-LTR promoter is active, resulting in hyperproliferation and neoplastic changes in Pten-null skin and prostate. These phenotypes had early onset and were completely penetrant. Abnormalities in Pten mutant skin consisted of mild epidermal hyperplasia, whereas prostates from these mice exhibited high-grade prostatic intraepithelial neoplasia (HGPIN) that frequently progressed to focally invasive cancer. These data demonstrate that Pten is an important physiological regulator of growth in the skin and prostate. Further, the early onset of HGPIN in Pten mutant males is unique to this animal model and implicates PTEN mutations in the initiation of prostate cancer. Consistent with high PTEN mutation rates in human prostate tumors, these data indicate that PTEN is a critical tumor suppressor in this organ.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14747659      PMCID: PMC341836          DOI: 10.1073/pnas.0308217100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

Review 1.  Getting under the skin of epidermal morphogenesis.

Authors:  Elaine Fuchs; Srikala Raghavan
Journal:  Nat Rev Genet       Date:  2002-03       Impact factor: 53.242

Review 2.  Molecular genetics of prostate cancer.

Authors:  C Abate-Shen; M M Shen
Journal:  Genes Dev       Date:  2000-10-01       Impact factor: 11.361

Review 3.  PTEN function in mammalian cell size regulation.

Authors:  Stéphanie Backman; Vuk Stambolic; Tak Mak
Journal:  Curr Opin Neurobiol       Date:  2002-10       Impact factor: 6.627

4.  Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways.

Authors:  Michael A Crackower; Gavin Y Oudit; Ivona Kozieradzki; Renu Sarao; Hui Sun; Takehiko Sasaki; Emilio Hirsch; Akira Suzuki; Tetsuo Shioi; Junko Irie-Sasaki; Rajan Sah; Hai-Ying M Cheng; Vitalyi O Rybin; Giuseppe Lembo; Luigi Fratta; Antonio J Oliveira-dos-Santos; Jeffery L Benovic; C Ronald Kahn; Seigo Izumo; Susan F Steinberg; Matthias P Wymann; Peter H Backx; Josef M Penninger
Journal:  Cell       Date:  2002-09-20       Impact factor: 41.582

Review 5.  Cowden disease or multiple hamartoma syndrome--cutaneous clue to internal malignancy.

Authors:  Susanna K Fistarol; Marc D Anliker; Peter H Itin
Journal:  Eur J Dermatol       Date:  2002 Sep-Oct       Impact factor: 3.328

6.  Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis.

Authors:  Minjung J Kim; Robert D Cardiff; Nishita Desai; Whitney A Banach-Petrosky; Ramon Parsons; Michael M Shen; Cory Abate-Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

7.  Pten inactivation alters peripheral B lymphocyte fate and reconstitutes CD19 function.

Authors:  Amy N Anzelon; Hong Wu; Robert C Rickert
Journal:  Nat Immunol       Date:  2003-02-03       Impact factor: 25.606

8.  Keratinocyte-specific Pten deficiency results in epidermal hyperplasia, accelerated hair follicle morphogenesis and tumor formation.

Authors:  Akira Suzuki; Satoshi Itami; Minako Ohishi; Koichi Hamada; Tae Inoue; Nobuyasu Komazawa; Haruki Senoo; Takehiko Sasaki; Junji Takeda; Motomu Manabe; Tak Wah Mak; Toru Nakano
Journal:  Cancer Res       Date:  2003-02-01       Impact factor: 12.701

9.  Critical roles of Pten in B cell homeostasis and immunoglobulin class switch recombination.

Authors:  Akira Suzuki; Tsuneyasu Kaisho; Minako Ohishi; Manae Tsukio-Yamaguchi; Takeshi Tsubata; Pandelakis A Koni; Takehiko Sasaki; Tak Wah Mak; Toru Nakano
Journal:  J Exp Med       Date:  2003-03-03       Impact factor: 14.307

10.  Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland.

Authors:  Gang Li; Gertraud W Robinson; Ralf Lesche; Hilda Martinez-Diaz; Zhaorong Jiang; Nora Rozengurt; Kay-Uwe Wagner; De-Chang Wu; Timothy F Lane; Xin Liu; Lothar Hennighausen; Hong Wu
Journal:  Development       Date:  2002-09       Impact factor: 6.868

View more
  60 in total

1.  Muscle-specific Pten deletion protects against insulin resistance and diabetes.

Authors:  Nadeeja Wijesekara; Daniel Konrad; Mohamed Eweida; Craig Jefferies; Nicole Liadis; Adria Giacca; Mike Crackower; Akira Suzuki; Tak W Mak; C Ronald Kahn; Amira Klip; Minna Woo
Journal:  Mol Cell Biol       Date:  2005-02       Impact factor: 4.272

2.  PI3K/mTOR signaling regulates prostatic branching morphogenesis.

Authors:  Susmita Ghosh; Hiu Lau; Brian W Simons; Jonathan D Powell; David J Meyers; Angelo M De Marzo; David M Berman; Tamara L Lotan
Journal:  Dev Biol       Date:  2011-10-08       Impact factor: 3.582

Review 3.  PTEN in DNA damage repair.

Authors:  Mei Ming; Yu-Ying He
Journal:  Cancer Lett       Date:  2012-01-18       Impact factor: 8.679

4.  The determinants of head and neck cancer: Unmasking the PI3K pathway mutations.

Authors:  Fernanda S Giudice; Cristiane H Squarize
Journal:  J Carcinog Mutagen       Date:  2013-08-02

Review 5.  Current mouse and cell models in prostate cancer research.

Authors:  Xinyu Wu; Shiaoching Gong; Pradip Roy-Burman; Peng Lee; Zoran Culig
Journal:  Endocr Relat Cancer       Date:  2013-06-24       Impact factor: 5.678

Review 6.  Genetically engineered mouse models of prostate cancer.

Authors:  Maxime Parisotto; Daniel Metzger
Journal:  Mol Oncol       Date:  2013-02-14       Impact factor: 6.603

7.  Lifelong accumulation of bone in mice lacking Pten in osteoblasts.

Authors:  Ximeng Liu; Katia J Bruxvoort; Cassandra R Zylstra; Jiarong Liu; Rachel Cichowski; Marie-Claude Faugere; Mary L Bouxsein; Chao Wan; Bart O Williams; Thomas L Clemens
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-07       Impact factor: 11.205

8.  Akt-dependent Pp2a activity is required for epidermal barrier formation during late embryonic development.

Authors:  Ryan F L O'Shaughnessy; Jonathan C Welti; Katherine Sully; Carolyn Byrne
Journal:  Development       Date:  2009-09-17       Impact factor: 6.868

9.  Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model.

Authors:  J Ai; L E Pascal; K J O'Malley; J A Dar; S Isharwal; Z Qiao; B Ren; L H Rigatti; R Dhir; W Xiao; J B Nelson; Z Wang
Journal:  Oncogene       Date:  2013-05-27       Impact factor: 9.867

10.  UVB-induced ERK/AKT-dependent PTEN suppression promotes survival of epidermal keratinocytes.

Authors:  M Ming; W Han; J Maddox; K Soltani; C R Shea; D M Freeman; Y-Y He
Journal:  Oncogene       Date:  2009-11-02       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.